Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859262 | 0.90 | CYP1A2 (0.64) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL10780629 | 0.85 | MEN1 (0.61) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL9036644 | 0.82 | CYP1A2 (0.68) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL6858071 | 0.82 | CYP1A2 (0.56) | MAPTKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL15147336 | 0.82 | GAA (0.46) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL881579 | 0.82 | LMNA (0.64) | MAPTKDM4EALDH1A1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL5119113 | 0.81 | CYP1A2 (0.66) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL8645476 | 0.80 | GPR35 (0.68) | MAPTKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL29537172 | 0.79 | CYP1A2 (0.75) | MAPTKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL2175829 | 0.79 | CYP1A2 (0.75) | MAPTKDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196986-A1 | TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2013-08-01 | — | — | US | disclosed |
| EP-0368237-B1 | Polymer bound flame retardants | ATOCHEM NORTH AMERICA (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5220015-A | Having hydrazide group to chemically bond to anhydride-containing polymers | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1993-06-15 | — | — | US | disclosed |
| US-5140070-A | Halogenated aromatic compounds having acylamino functional groups bonded to imide containing polymer | ELF ATOCHEM NORTH AMERICA, INC (US) | 1992-08-18 | — | — | US | disclosed |
| US-5037894-A | Maleic anhydride polymer reacted with halogenated hydrazide compound or derivative | ATOCHEM NORTH AMERICA, INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0368237-A2 | Polymer bound flame retardants | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0126326-B1 | PROCESS FOR PREPARING 1,2,4-TRIAZOLE-3-CARBOXAMIDES | UBE INDUSTRIES, LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4578479-A | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0126326-A1 | Process for preparing 1,2,4-triazole-3-carboxamides | UBE INDUSTRIES, LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196986-A1 | TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | MAPT 3912/4885KDM4E 2324/4885ALDH1A1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.